Analysts Set ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Price Target at $107.33

Shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) have been given an average recommendation of “Moderate Buy” by the eight ratings firms that are currently covering the stock, Marketbeat Ratings reports. Three analysts have rated the stock with a hold recommendation and five have issued a buy recommendation on the company. The average 12 month price target among brokerages that have covered the stock in the last year is $107.3333.

A number of equities analysts have issued reports on the stock. Wall Street Zen upgraded shares of ANI Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Saturday, May 9th. Weiss Ratings reiterated a “hold (c+)” rating on shares of ANI Pharmaceuticals in a research report on Monday, June 1st. Finally, Zacks Research cut shares of ANI Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Thursday, May 14th.

ANI Pharmaceuticals Stock Performance

ANI Pharmaceuticals stock opened at $81.20 on Friday. The company has a quick ratio of 2.52, a current ratio of 3.12 and a debt-to-equity ratio of 1.06. The company has a market capitalization of $1.85 billion, a PE ratio of 20.56 and a beta of 0.44. The firm has a fifty day simple moving average of $79.35 and a two-hundred day simple moving average of $79.37. ANI Pharmaceuticals has a twelve month low of $61.17 and a twelve month high of $99.50.

ANI Pharmaceuticals (NASDAQ:ANIP) last posted its quarterly earnings results on Friday, May 8th. The specialty pharmaceutical company reported $2.05 earnings per share for the quarter, topping the consensus estimate of $1.28 by $0.77. ANI Pharmaceuticals had a net margin of 9.98% and a return on equity of 27.51%. The business had revenue of $237.46 million during the quarter, compared to the consensus estimate of $207.63 million. During the same period in the previous year, the firm posted $1.70 earnings per share. The firm’s revenue for the quarter was up 20.5% on a year-over-year basis. ANI Pharmaceuticals has set its FY 2026 guidance at 9.190-9.690 EPS. Research analysts expect that ANI Pharmaceuticals will post 8.07 EPS for the current year.

Insider Activity at ANI Pharmaceuticals

In related news, Director Patrick D. Walsh sold 10,000 shares of the stock in a transaction that occurred on Wednesday, May 13th. The shares were sold at an average price of $80.63, for a total transaction of $806,300.00. Following the transaction, the director owned 38,432 shares in the company, valued at $3,098,772.16. This represents a 20.65% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Nikhil Lalwani sold 55,000 shares of the stock in a transaction that occurred on Monday, May 11th. The shares were sold at an average price of $77.57, for a total transaction of $4,266,350.00. Following the transaction, the chief executive officer owned 349,889 shares in the company, valued at approximately $27,140,889.73. This trade represents a 13.58% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 80,178 shares of company stock valued at $6,256,052 over the last three months. Corporate insiders own 8.10% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the business. Divisadero Street Capital Management LP purchased a new stake in shares of ANI Pharmaceuticals in the third quarter worth $21,454,000. Apis Capital Advisors LLC increased its stake in shares of ANI Pharmaceuticals by 28.1% in the third quarter. Apis Capital Advisors LLC now owns 164,000 shares of the specialty pharmaceutical company’s stock worth $15,022,000 after purchasing an additional 36,000 shares in the last quarter. Oliver Luxxe Assets LLC purchased a new stake in shares of ANI Pharmaceuticals in the fourth quarter worth $1,823,000. Vanguard Group Inc. increased its stake in shares of ANI Pharmaceuticals by 2.2% in the fourth quarter. Vanguard Group Inc. now owns 1,305,068 shares of the specialty pharmaceutical company’s stock worth $103,022,000 after purchasing an additional 27,598 shares in the last quarter. Finally, Artemis Investment Management LLP purchased a new stake in shares of ANI Pharmaceuticals in the fourth quarter worth $1,706,000. 76.05% of the stock is currently owned by institutional investors.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.